Elizabeth is Counsel in our global antitrust, competition and trade practice, based in Washington, DC.
Elizabeth represents clients on a broad range of antitrust issues, with a focus on US and global merger control and review, conduct and market investigations by US and foreign antitrust agencies, and corporate compliance programs. She has particular experience in the technology, life sciences, and financial services sectors.
Prior to rejoining Freshfields, Elizabeth was a member of the antitrust practice of another major law firm where she advised technology and life sciences clients facing novel antitrust issues and guided them through global merger control processes.
Elizabeth is dual qualified in the US and England and Wales. She has spent time in our London and Dusseldorf offices and also was seconded to the London Stock Exchange Group where she advised on competition and commercial matters.
- Figma on its proposed $20bn acquisition by Adobe*
- Maze Therapeutics on proposed acquisition of an exclusive license by Sanofi, including an in-depth investigation by the US FTC*
- Shockwave Medical on its $13bn acquisition by Johnson & Johnson*
- Squarespace on the sale of Tock to American Express and its combination with Resy*
- DICE Therapeutics on its $2.4bn acquisition by Eli Lilly*
- Morphic Holdings on its $3.2bn acquisition by Eli Lilly*
- Clif Bar on its $2.9bn acquisition by Mondelez*
- UserTesting on its $1.3bn acquisition by Thoma Bravo and Sunstone Partners and its subsequent combination with User Zoom*
- AppLovin on its $1bn acquisition of Twitter’s MoPub business*
- Alpine Immune Sciences on its $4.9bn acquisition by Vertex Pharmaceuticals*
- AstraZeneca on its $39bn acquisition of Alexion including securing unconditional clearance in more than 20 antitrust and foreign direct investment jurisdictions
- The London Stock Exchange Group on the US and global merger control aspects of its $27bn deal to acquire Refinitiv
- A telecommunications company on its $5bn sale of its media group to Apollo
- CK Hutchison on its proposed acquisition of Telefonica UK
- Sivantos and its controlling shareholder EQT on its $8.3bn merger with Widex
- Johnson & Johnson on its $30bn acquisition of Actelion Pharmaceuticals
- Global banks in connection with investigations by the UK’s CMA and the European Commission
- A publicly traded consumer facing technology platform in relation to a US Department of Justice Antitrust Division Section 8 investigation*
*Includes experience from prior firm
700 13th Street, NW
10th Floor